Pear Therapeutics has captured its second FDA thumbs-up for a clinical-grade app with the Dec. 10-announced 510(k) clearance of its reSET-O app for opioid use disorder.
Pharma-firm Sandoz, a Novartis subsidiary, is preparing to launch the app, which the company and FDA says can increase an...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?